Searched for
PHARMACEUTICAL MANUFACTURING
Cipla expects sequential recovery in North America on new product launches despite tariff uncertaintyCipla reported a 39% drop in net profit to ₹789 crore for the June quarter due to weakness in its North America business and margin compres...- Akums to acquire Oriflame India's manufacturing businessAkums Drugs and Pharmaceuticals will acquire Oriflame India's manufacturing business. This significant deal is valued at fifty-six crore ru...
- 'I expect India to be concerned about US pharma tariffs': Rubio on Trump's 200% stormUS Secretary of State Marco Rubio anticipates Indian concern over new generic drug import tariffs. These tariffs will rise significantly af...
- Pharma stocks slide as Trump's 100% generic drug tariff plan spooks investorsIndian drug shares declined Wednesday following US President Trump's tariff announcement. These proposed tariffs will significantly impact ...
- Tariffs alone will not produce sustainable generic medicine in US: IPAThe Indian Pharmaceutical Alliance believes tariffs alone will not build US generic drug manufacturing. Broader reforms are needed for fair...
- Food products lead PLI job creation, outpace electronics and pharmaFood processing leads PLI employment, creating jobs with minimal investment. Electronics manufacturing attracted significant capital but ge...
- Explained: What Donald Trump's up to 200% pharma tariffs mean for Indian investorsDonald Trump's announcement of tariffs of up to 200% on pharmaceutical imports triggered a selloff in Indian pharma stocks. However, analys...
- Indian pharma firms may yet survive Trump's 200% tariff bombshellDonald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say...
- 200% Trump tariff shock? India’s cheap pills may still beat US rivalsUS President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical expor...
- Trump’s 100% generic drug duty threatens US low-cost supplyPresident Donald Trump has given generic drugmakers two years to shift manufacturing to the US or face 100% import tariffs from August 2028...
- Trump's Generic Drug Tariffs Explained: What it means for Indian pharma before the 200% stormTrump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufactur...
- Trump's 200% drug tariff plan: Is India's pharma industry about to face an economic storm?The United States is set to implement a phased approach to tariffs on generic drug imports, beginning at zero percent and escalating to one...
- Hikal commissions cGMP pilot plant in Pune to strengthen pharmaceutical developmentHikal has commissioned an enhanced cGMP pilot plant at its Pune campus to strengthen its integrated capabilities for pharmaceutical develop...
- Trump announces new generic drugs tariff plan: No tariffs for 2 years, then 100%, and then 200%For Indian exporters, the two-year tariff-free period offers additional time to reassess supply chains and investment plans. While the imme...
- Sun Pharma, Cipla & other pharma stocks shed over 2% as Trump announces up to 200% tariffs on generic drugs from 2028Pharma stocks, including Sun Pharma, Cipla, Lupin and Dr Reddy's, fell up to 2.5% after US President Donald Trump announced a phased tariff...
- Risk is integral to the market; but there are different kinds of risk: 6 mid-cap stocks with upside potential of up to 21%We are in uncertain and volatile times. Does that mean investors should just sit out the downturn? While that is an option, the better opti...
- Emcure Pharma gets CDSCO nod to market Poviztra for fatty liver treatmentEmcure Pharmaceuticals announced its brand Poviztra is now available for fatty liver treatment. This follows regulatory approval for treati...
- Natco Pharma shares surge 5% after US FDA's tentative nod Olaparib tabletsNatco Pharma shares rose sharply on Monday after the U.S. FDA granted tentative approval for its generic Olaparib tablets, a bioequivalent ...
- Alembic Pharma partner NATCO gets USFDA tentative nod for generic Olaparib tablets; US market size at USD 1.4 bnAlembic Pharmaceuticals and NATCO Pharma received tentative USFDA approval for generic Olaparib tablets. This approval is for a cancer drug...
- India-UK FTA projected to boost Indian pharma exports by over 8% to $981 million in FY27: PharmexcilIndian pharmaceutical exports to the United Kingdom are projected to grow significantly. The India-UK Comprehensive Economic and Trade Agre...
Load More
